Open AccessCombination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
Author(s) -
Nilofer S. Azad,
Edwin M. Posadas,
Virginia E. Kwitkowski,
Seth M. Steinberg,
Lokesh Jain,
Christina M. Annunziata,
Lori M. Minasian,
Gisele Sarosy,
Herbert L. Kotz,
Ahalya Premkumar,
Liang Cao,
Deborah McNally,
Catherine Chow,
Alice Chen,
John J. Wright,
William D. Figg,
Elise C. Kohn
Publication year - 2008
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2007.10.8332
Subject(s) - medicine , sorafenib , bevacizumab , toxicity , adverse effect , oncology , vascular endothelial growth factor , renal cell carcinoma , ovarian cancer , proteinuria , sunitinib , gastroenterology , pharmacology , cancer , urology , chemotherapy , hepatocellular carcinoma , vegf receptors , kidney
Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor. Bevacizumab is a monoclonal antibody targeted against VEGF. We hypothesized that the complementary inhibition of VEGF signaling would have synergistic therapeutic effects.